You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 87 No. 4, APRIL 1951 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

TRIETHYLENE MELAMINE IN THE TREATMENT OF NEOPLASTIC DISEASE

A Compound with Nitrogen-Mustard-like Activity Suitable for Oral and Intravenous Use

D. A. KARNOFSKY, M.D.; J. H. BURCHENAL, M.D.; G. C. ARMISTEAD, Jr., M.D.; C. M. SOUTHAM, M.D.; J. L. BERNSTEIN, M.D.; L. F. CRAVER, M.D.; C. P. RHOADS, M.D.

AMA Arch Intern Med. 1951;87(4):477-516.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE NITROGEN mustards were introduced into medical practice in 1946 for the palliative treatment of the lymphomas, leukemias and other types of neoplastic disease.1 The most commonly administered nitrogen mustard is methyl-bis (2-chloroethyl) amine hydrochloride (HN2), and, since 1946, much experience has been gained from its use throughout the world.2 This nitrogen mustard has found a useful place as a temporary palliative agent in the management of certain types and stages of neoplastic disease. It must be injected intravenously, and it frequently produces severe nausea and vomiting; consequently, its administration, in most cases, has been regarded as a hospital procedure. Extravasation of the injected solution will produce a prolonged and painful local reaction, and, in patients receiving repeated courses of treatment, venous thromboses and difficulty in finding suitable veins for injection may occur. The dosage must be carefully controlled, since an excessive dose will produce serious, prolonged . . . [Full Text PDF of this Article]


Author Affiliations

NEW YORK

From the Chemotherapy Service, Memorial Center for Cancer and Allied Diseases.


Footnotes

Triethylene melamine was supplied in tablet form by Lederle Laboratories Division, American Cyanamid Company, Pearl River, N. Y.

This study was aided by the American Cancer Society, the National Cancer Institute of the United States Public Health Service, the Damon Runyon Memorial Fund for Cancer Research and the Babe Ruth Cancer Fund of the American Cancer Society.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1951 American Medical Association. All Rights Reserved.